

Index

abdominal ectopic pregnancy, 56–57	early intrauterine pregnancy, 4–11 week	implantation site, 76–77
adnexal pathology, 59	chorionic bumps, 14–15	inhomogeneous mass, 40–45
adnexal pathology, benign adnexal lesions	crown rump length (CRL), 11	interstitial ectopic pregnancy, 50, 79
benign ovarian neoplasms, 60–62	diagnosis landmarks, 11–12	diagnosis, 50–51
corpus luteum cysts, 59–60	echogenic coelomic fluid, 15	intramural pregnancy, 54–56, 79–80
cystadenofibromas, 62	fluid in endometrial cavity, 15	intra-uterine contraceptive devices (IUDs), 66
decidualisation, 61f8.7	multiple pregnancy diagnosis, 11–14	hysteroscopic sterilisation devices, Essure System (Bayer), 67
endometriomas, 61	ultrasound measurements, mean CRL, 11–14	pregnancy with IUD, 66
follicular/simple cysts, 59–60	umbilical cord cysts, 14–15	intrauterine pregnancy (IUP), 33
hydrosalpinx, 62–63	variants of normal, 14–15	
luteomas, 59–60	early pregnancy ultrasound scan (USS) provision of care standards, 1–2	luteomas, 59–60
mature teratomas, dermoid cysts, 60–61, 62–63	setting, 1–2	
mucinous cystadenomas, 62	use of, aims, 1	malignant adnexal masses, 62–63
non-neoplastic ovarian lesions, 59–60	echogenic coelomic fluid, 15	mature teratomas, dermoid cysts, 60–61, 62–63
ovarian fibromas, fibrothecomas, 60–62	endometriomas, 61	miscarriage diagnosis
paraovarian cysts, 62–63	endometrium, 40–46	aetiology, 17–18
serous cystadenomas, 61		caution, adherence to guidelines, counselling, 20
theca-lutein cysts, 60	failed PUL (FPUL), 33	presentation, 18
adnexal pathology, malignant adnexal masses, 62–63	fibroids, 64	soft markets, prediction of miscarriage, 20
appendicitis, 65	fluid in endometrial cavity, 15	terminology, 17–18
auditable standards, 9	follicular/simple cysts, 59–60	ultrasound criteria, diagnosis, 18–19
	free pelvic fluid, 40–45	mucinous cystadenomas, 62
benign adnexal lesions. <i>See</i> adnexal lesions, benign adnexal lesions	gestational trophoblastic disease (GTD), 78–79	multiple pregnancy diagnosis, 11–14
benign ovarian neoplasms, 60–62	epidemiology, 23–24	
	genetics, 23	non-neoplastic ovarian lesions, 59–60
caesarean scar pregnancy, 80	histopathology, 23–26	nontubal ectopic pregnancy. <i>See also</i> tubal ectopic pregnancy
diagnosis, 54–55	main features comparison, 23–24	abdominal ectopic pregnancy, 56–57
cervical pregnancy, 52	gestational trophoblastic neoplasia (GTN), 31	caesarean scar ectopic pregnancy, 53
diagnosis, 52–53		caesarean scar ectopic pregnancy, diagnosis, 54–55
chorionic bumps, 14–15	heterotopic pregnancy, 40	cervical pregnancy, 52
complete hydatidiform moles (CHMs)	hGC ratio, 36	cervical pregnancy, diagnosis, 52–53
clinical presentation, 24–26	human chorionic gonadotrophin, 23	cornual pregnancy, 52
ultrasound features, 26–29	hydatidiform moles (HMs)	cornual pregnancy, diagnosis, 52
cornual pregnancy, 52, 80	clinical presentation, 23–27	interstitial ectopic, 50
diagnosis, 52	management, 29	interstitial ectopic, diagnosis, 50–51
corpus luteum (CL)	post evacuation monitoring, 31	intramural pregnancy, 54–56
identification, 75–76	ultrasound diagnosis, 26	ovarian ectopic pregnancy, 56
corpus luteum cysts, 59–60	hydrosalpinx, 62–63	ultrasonic criteria for diagnosis, summary table, 57t7.1
crown rump length (CRL), 11		
cystadenofibromas, 62	images. <i>See also</i> ultrasound technique, image optimisation	
	documentation, storage, 5–9	
decidualisation, 61f8.7		

Index

- ovarian ectopic pregnancy, 56
- ovarian fibromas, fibrothecomas, 60–62
- paraovarian cysts, 62–63
- partial hydatidiform moles (PHMs)
 - clinical presentation, 27t4.3
 - ultrasound features, 27
- pelvic kidney, 65–66
- peritoneal pseudocysts, 64
- persistent PUL (PPUL), 33–34, 36–37
- pregnancy of unknown location (PUL)
 - presentation, 33–34
 - ultrasound findings, 34–35
- pregnancy of unknown location (PUL), clinical outcomes
 - ectopic pregnancy (EP), 33
 - failed PUL (FPUL), 33
 - intrauterine pregnancy (IUP), 33
 - persistent PUL (PPUL), 33–34, 36–37
- pregnancy of unknown location (PUL), management
 - hCG ratio, 36
 - M6 model, 36–37
 - risk prediction models, 36–37
 - serum hCG, 35
 - serum progesterone, 35
- retained products of conception (RPOC), 77–78
- safety, 1
 - indices, 1–2
 - mechanical index (MI), thermal index (TI), 3f1.1
 - scanning modes, 1
- serous cystadenomas, 61
- serum hCG, 35
- serum progesterone, 35
- theca-lutein cysts, 60
- 3-Dimensional (3-D) ultrasound, early pregnancy
 - caesarean scar pregnancy, 80
 - cornual pregnancy, 80
 - interstitial pregnancy, 79
 - intramural pregnancy, 79–80
 - location of pregnancy, 79
 - uterine anomalies, 80–81
- 3-Dimensional (3-D) ultrasound and colour Doppler (CD)
 - clinical applications, early pregnancy, 75–79
 - corpus luteum (CL)
 - identification, 75–76
 - gestational trophoblastic disease, 78–79
 - implantation site, 76–77
 - retained products of conception (RPOC), 77–78
 - safety, 75
 - uterine arteriovenous malformation (AVM), 77–78
 - viability assessment, 77
- transabdominal scan (TAS)
 - procedure, methodology, 5
- transvaginal scan (TVS) *vs.*, 3
- transvaginal scan (TVS)
 - procedure, methodology, 4
- transabdominal scan (TAS) *vs.*, 3
- tubal ectopic pregnancy (EP), 33
 - aetiology, 39
 - biochemical investigations, 45–48
 - diagnosis. sonographic criteria, 39–40
- empty gestational sac, sac with/without yolk sac or fetal pole, 6
- endometrium, 40–46
- free pelvic fluid, 40–45
- heterotopic pregnancy, 40
- inhomogeneous mass, 40–45
- management factors, 48t6.4
- nonspecific indicative findings, 40–46
- presentation, 39
- risk factors, 39
- sites, 39
- surgical diagnosis, 48
- ultrasound measurements, mean CRL, 11–14
- ultrasound technique, image optimisation
 - depth, 3
 - focus, 3
 - frequency, 4
 - gain, 3
 - image orientation, 3
 - magnification, 3
- umbilical cord cysts, 14–15
- uterine anomalies, 80–81
- uterine anomalies, early pregnancy
 - anomaly types, screening, diagnosis, 69–70
 - effect on pregnancy, 69
 - image manipulation, 70–74
 - prevalence, 69
 - 3D ultrasound, 70
 - treatment, 74
- uterine arteriovenous malformation (AVM), 77–78